Samsung Biologics Co Ltd (207940 KO) stock market data APIs
₩999999.9999
0(0%)
as of January 17, 2025
Samsung Biologics Co Ltd Financial Data Overview
Price chart is built with
Anychart
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Prev. Close
999999.9999
Open
999999.9999
Volume
47 539
High
999999.9999
Low
999999.9999
52 wk Range
721000-999999.9999
Market Cap
72 241 610 M
Shares Outstanding
71 174 K
Revenue
4 211 290 M
Beta
0.323
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Samsung Biologics Co Ltd data using free add-ons & libraries
Get Samsung Biologics Co Ltd Fundamental Data
Samsung Biologics Co Ltd Fundamental data includes:
- Net Revenue: 4 211 290 M
- EBITDA: 1 896 241 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-22
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Samsung Biologics Co Ltd News
New
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabili...
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise INCHEON, South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biolo...
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's ded...
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
